- Home
- RDHL vs ENSC Comparison
RDHL vs ENSC Comparison
Compare RDHL & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- ENSC
- Stock Information
- Founded
- RDHL 2009
- ENSC 2003
- Country
- RDHL Israel
- ENSC United States
- Employees
- RDHL N/A
- ENSC N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- ENSC Health Care
- Exchange
- RDHL Nasdaq
- ENSC Nasdaq
- Market Cap
- RDHL 3.8M
- ENSC 4.9M
- IPO Year
- RDHL N/A
- ENSC N/A
- Fundamental
- Price
- RDHL $2.02
- ENSC $2.28
- Analyst Decision
- RDHL
- ENSC
- Analyst Count
- RDHL 0
- ENSC 0
- Target Price
- RDHL N/A
- ENSC N/A
- AVG Volume (30 Days)
- RDHL 19.3K
- ENSC 64.8K
- Earning Date
- RDHL 08-28-2025
- ENSC 08-13-2025
- Dividend Yield
- RDHL N/A
- ENSC N/A
- EPS Growth
- RDHL N/A
- ENSC N/A
- EPS
- RDHL N/A
- ENSC N/A
- Revenue
- RDHL $8,042,999.00
- ENSC $6,224,081.00
- Revenue This Year
- RDHL $381.91
- ENSC N/A
- Revenue Next Year
- RDHL N/A
- ENSC $1,381.48
- P/E Ratio
- RDHL N/A
- ENSC N/A
- Revenue Growth
- RDHL 23.17
- ENSC 256.35
- 52 Week Low
- RDHL $1.71
- ENSC $1.62
- 52 Week High
- RDHL $20.28
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- RDHL 57.04
- ENSC 53.77
- Support Level
- RDHL $1.75
- ENSC $2.15
- Resistance Level
- RDHL $2.08
- ENSC $2.34
- Average True Range (ATR)
- RDHL 0.10
- ENSC 0.10
- MACD
- RDHL 0.03
- ENSC 0.03
- Stochastic Oscillator
- RDHL 85.16
- ENSC 90.63
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.